PT  - JOURNAL ARTICLE
AU  - Can, Melike Hazal
AU  - Sweeney, Sedona
AU  - Allwood, Brian W.
AU  - Dorman, Susan E.
AU  - Cohen, Ted
AU  - Menzies, Nicolas A.
TI  - Implications of progressive lung damage and post-TB sequelae for the health benefits of prompt TB diagnosis in high HIV prevalence settings: a mathematical modeling analysis
AID  - 10.1101/2024.08.12.24311198
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.12.24311198
4099  - http://medrxiv.org/content/early/2024/08/17/2024.08.12.24311198.short
4100  - http://medrxiv.org/content/early/2024/08/17/2024.08.12.24311198.full
AB  - Background Untreated pulmonary tuberculosis (TB) causes ongoing lung damage, which may persist after treatment. Conventional approaches for assessing TB health effects may not fully capture these mechanisms. We evaluated how TB-associated lung damage and post-TB sequalae affect the lifetime health consequences of TB in high HIV prevalence settings.Methods We developed a microsimulation model representing dynamic changes in lung function for individuals evaluated for TB in routine clinical settings. We parameterized the model with data for Uganda, Kenya, and South Africa, and estimated lifetime health outcomes under prompt, delayed, and no TB treatment scenarios. We compared results to earlier modelling approaches that omit progressive lung damage and post-TB sequelae.Findings We estimated 4.6 (95% uncertainty interval 3.4–5.8), 7.2 (5.1–9.6), and 18.0 (15.1–20.0) year reductions in life expectancy due to TB under prompt, delayed, and no treatment scenarios, respectively. Disability-adjusted life years (DALYs) from TB were estimated as 8.3 (6.2–10.6), 12.6 (9.0–17.0), and 27.8 (24.1–30.6) under prompt, delayed, and no treatment scenarios, respectively. Post-TB DALYs represented 9–53% of total DALYs. Modelling approaches that omit progressive lung damage and post-TB sequelae underestimated lifetime health losses of TB by 48–57%, and underestimated the benefits of prompt treatment by 45–64%.Interpretation Delayed initiation of TB treatment causes greater lung damage and higher mortality risks during and after the disease episode. In settings with co-prevalent TB and HIV, accounting for these factors substantially increased estimates of the lifetime disease burden and life expectancy loss caused by TB.Funding NIH.Evidence before this study Research on long-term sequalae among tuberculosis (TB) survivors has focused on describing the prevalence and nature of these post-TB sequalae, and quantifying their contribution to the overall burden of TB disease. There is limited evidence describing how improvements in TB diagnosis and prompt treatment initiation could affect the overall health losses associated with TB, inclusive of post-TB sequelae. We searched PubMed from database inception until July 19, 2024, with no language restrictions for studies reporting how TB diagnosis and treatment affect post-TB sequelae and lifetime health losses, using the search terms “(tuberculosis OR TB) AND (post-TB OR post-tuberculosis) AND (diagnos*) AND (treat*) AND (model*)”. We retrieved 21 publications based on this search. Of these, one study reported a mathematical modeling approach for estimating lifetime health outcomes and costs by considering the delay in diagnosis, post-TB sequelae, and treatment discontinuation among TB patients in Brazil, but did not simulate changes in lung function during the TB episode.Added value of this study To our knowledge, this is the first study to investigate the effects of timeliness of TB diagnosis on progressive lung damage and lifetime health outcomes for individuals with TB. To do so, we constructed a mathematical model simulating changes in lung function before, during, and after TB treatment, and simulated multiple counterfactual scenarios for a cohort of individuals presenting to primary health services with undiagnosed TB disease in Uganda, Kenya, and South Africa. We compared the results of this analysis to the estimates produced by earlier modelling approaches that do not represent TB-associated lung damage or post-TB sequelae.Implications of all the available evidence The results of this analysis showed that post-TB sequelae represent a substantial share of the overall health losses associated with TB, and that better post-TB lung function (resulting from a shorter duration of untreated TB disease) is a major contributor to the overall health benefits of prompt TB diagnosis and treatment. These results are not accurately captured by earlier modelling approaches that did not consider TB-associated lung damage or post-TB sequelae. The findings of this analysis contribute to the evidence base describing how TB interventions can influence lung function dynamics during and after TB disease, and the resulting changes in disability and mortality due to TB.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under award number U01AI152084. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Harvard T.H. Chan School of Public Health gave ethical approval for this work (IRB21-0709). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.